Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ardelyx ( (ARDX) ) has provided an update.
On April 30, 2026, Ardelyx reported first quarter 2026 product revenue of $93.4 million, up 38% year over year, driven by strong adoption of IBSRELA and XPHOZAH. IBSRELA revenue rose 58% to $70.1 million and XPHOZAH contributed $23.3 million, while the company ended March 31, 2026 with $238.1 million in cash, cash equivalents and investments and narrowed its net loss to $37.6 million from $41.1 million a year earlier.
Management reiterated full-year 2026 revenue guidance of $410 million to $430 million for IBSRELA and $110 million to $120 million for XPHOZAH, underscoring confidence in continued demand growth. Ardelyx is investing heavily in its pipeline and commercialization, advancing the Phase 3 ACCEL trial of IBSRELA in chronic idiopathic constipation, progressing next-generation NHE3 inhibitor RDX10531, expanding leadership, and refinancing debt on better terms to support long-term growth and shareholder value.
The most recent analyst rating on (ARDX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Ardelyx stock, see the ARDX Stock Forecast page.
Spark’s Take on ARDX Stock
According to Spark, TipRanks’ AI Analyst, ARDX is a Neutral.
The score is weighed down primarily by weak financial quality—ongoing losses, negative free cash flow, and higher leverage—despite strong revenue growth and high gross margins. Technical signals are also soft (below the 20-day average with negative MACD). Offsetting these are constructive earnings call takeaways, including strong 2026 revenue guidance, improved cash dynamics, and pipeline/IP progress, but higher planned spending and XPHOZAH reimbursement headwinds temper the outlook.
To see Spark’s full report on ARDX stock, click here.
More about Ardelyx
Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for significant unmet medical needs. The U.S.-based group currently markets two tenapanor-based products, IBSRELA for irritable bowel syndrome with constipation in adults and XPHOZAH for reducing serum phosphorus in chronic kidney disease patients on dialysis.
Average Trading Volume: 3,554,418
Technical Sentiment Signal: Buy
Current Market Cap: $1.47B
For an in-depth examination of ARDX stock, go to TipRanks’ Overview page.